Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy. Issue 4 (28th June 2021)

• Record Type: Journal Article
• Authors: McPherson, Kerry Silva; Korzhnev, Dmitry M.
• Is Part Of: RSC chemical biology. Volume 2:Issue 4(2021)
• Page Start: 1167
• Page End: 1195
• Publication Date: 2021-06-28
• Subjects: 572
• DOI: 10.1039/d1cb00101a
• Languages: English
• ISSNs: 2633-0679

Abstract

Abstract : Targeting protein–protein interactions within the DNA damage response (DDR) pathways with small molecule inhibitors is reviewed here as a strategy to design novel cancer chemotherapeutics. Abstract : Cellular DNA damage response (DDR) is an extensive signaling network that orchestrates DNA damage recognition, repair and avoidance, cell cycle progression and cell death. DDR alteration is a hallmark of cancer, with the deficiency in one DDR capability often compensated by a dependency on alternative pathways endowing cancer cells with survival and growth advantage. Targeting these DDR pathways has provided multiple opportunities for the development of cancer therapies. Traditional drug discovery has mainly focused on catalytic inhibitors that block enzyme active sites, which limits the number of potential drug targets within the DDR pathways. This review article describes the emerging approach to the development of cancer therapeutics targeting essential protein–protein interactions (PPIs) in the DDR network. The overall strategy for the structure-based design of small molecule PPI inhibitors is discussed, followed by an overview of the major DNA damage sensing, DNA repair, and DNA damage tolerance pathways with a specific focus on PPI targets for anti-cancer drug design. The existing small molecule inhibitors of DDR PPIs are summarized that selectively kill cancer cells and/or sensitize cancers to front-line genotoxic therapies, and a range of new PPI targets are proposed that may lead to the development of novel chemotherapeutics.